Table 2 AXL-targeted drugs in clinical trials
From: AXL in cancer: a modulator of drug resistance and therapeutic target
Drug | Cancer | Combination with | Clinical Trial No | Phase |
|---|---|---|---|---|
Bemcentinib (BGB324, R428) | Advanced Adenocarcinoma of the Lung | Pembrolizumab | NCT03184571 | Phase 2 |
| Â | Triple Negative Breast Cancer | Pembrolizumab | NCT03184558 | Phase 2 |
| Â | Stage IIIb or Stage IV non-small cell lung cancer (NSCLC) | Erlotinib | NCT02424617 | Phase 1/2 |
| Â | Advanced or metastatic non-squamous NSCLC | Pembrolizumab/ Pemetrexed/ Carboplatin | NCT05469178 | Phase 1/2 |
| Â | Acute Myeloid Leukemia (AML) | Cytarabine/ Decitabine | NCT02488408 | Phase 1/2 |
Dubermatinib (TP-0903) | FLT3 gene mutated AML | Azacitidine | NCT04518345 | Phase 1/2 |
DS-1205c | Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant NSCLC | Osimertinib | NCT03255083 | Phase 1 |
| Â | Metastatic or Unresectable EGFR-Mutant NSCLC | Gefitinib | NCT03599518 | Phase 1 |
BA3011 (CAB-AXL-ADC) | Metastatic NSCLC | PD-1 inhibitor | NCT04681131 | Phase 2 |
| Â | Solid tumors | PD-1 inhibitor | NCT03425279 | Phase 1/2 |
AVB-S6-500 (batiraxcept) | Advanced Urothelial Carcinoma | Avelumab | NCT04004442 | Phase 1 |
| Â | Advanced Pancreatic Adenocarcinoma | Nab paclitaxel/ Gemcitabine | NCT04983407 | Phase 1/2 |
| Â | Platinum-Resistant Recurrent Ovarian Cancer (OC) | Paclitaxel/ Pegylated liposomal doxorubicin | NCT03639246 | Phase 1 |
| Â | Platinum-Resistant Recurrent OC | Paclitaxel | NCT04729608 | Phase 3 |
| Â | Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Durvalumab | NCT04019288 | Phase 1/2 |
| Â | Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) | Cabozantinib/ Nivolumab | NCT04300140 | Phase 1/2 |
ONO-7475 | Acute Leukemias | Venetoclax | NCT03176277 | Phase 1/2 |
Merestinib (LY2801653) | Relapsed or Refractory AML | LY2874455 | NCT03125239 | Phase 1 |
| Â | Advanced or Metastatic Cancer | Cisplatin/ Gemcitabine | NCT03027284 | Phase 1 |
| Â | Advanced Refractory Solid Tumors | LY3300054 | NCT02791334 | Phase 1 |
| Â | Advanced Cancers | Ramucirumab (LY3009806) | NCT02745769 | Phase 1 |
| Â | Advanced or Metastatic Biliary Tract Cancer | cisplatin and gemcitabine | NCT02711553 | Phase 2 |
Sitravatinib (MGCD516) | Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy | Tislelizumab | NCT05614453 | Phase 2 |
| Â | hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection | Tislelizumab | NCT05407519 | Phase 2 |
| Â | HCC at high risk of recurrence after curative resection | Tislelizumab | NCT05564338 | Phase 3 |
| Â | ccRCC | Nivolumab | NCT03680521 | Phase 2 |
| Â | Recurrent Endometrial Cancer and Other Solid Tumors with Deficient Mismatch Repair System | Pembrolizumab | NCT05419817 | Phase 2 |
| Â | Advanced Non-Squamous NSCLC | Nivolumab | NCT03906071 | Phase 3 |
| Â | Metastatic or Advanced ccRCC | Nivolumab | NCT04904302 | Phase 2 |
|  | Advanced Treatment-Naïve PD-L1 + Non-Squamous NSCLC | Pembrolizumab | NCT04925986 | Phase 2 |
| Â | Advanced, Unresectable NSCLC | Tislelizumab | NCT05176925 | Phase 2 |
| Â | Extensive stage small cell lung cancer | Tislelizumab | NCT05228496 | Phase 2 |
| Â | Advanced or Metastatic NSCLC | Tislelizumab | NCT04921358 | Phase 3 |
| Â | Unresectable or Metastatic Melanoma | Tislelizumab | NCT05104801 | Phase 2 |
| Â | Esophageal Squamous Cell Carcinoma | Tislelizumab | NCT05461794 | Phase 2 |
| Â | Recurrent or Metastatic TNBC | Tislelizumab | NCT04734262 | Phase 2 |
| Â | Metastatic Uveal Melanoma with Liver Metastases | Tislelizumab | NCT05542342 | Phase 2 |
| Â | NSCLC | Nivolumab | NCT02954991 | Phase 2 |
| Â | Urothelial Carcinoma | Nivolumab/ Pembrolizumab/ Enfortumab vedotin | NCT03606174 | Phase 2 |
| Â | Advanced Solid Tumors | Tislelizumab | NCT03666143 | Phase 1 |
| Â | Advanced or Metastatic HCC or Gastric/Gastroesophageal Junction Cancer (GC/GEJC) | Tislelizumab | NCT03941873 | Phase 1/2 |